EN DE
STOCK COMPARISON

McKesson vs Novolog Pharm-Up 1966: Fair Value & Quality

Both stocks run through our valuation models. Here is how McKesson (MCK) and Novolog Pharm-Up 1966 (NVLG) compare, as of Sep 25, 2026.

As of Sep 25, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: McKesson trades at $881 versus a fair value of $819 (-7%), while Novolog Pharm-Up 1966 trades at ILS 0.84 versus ILS 0.23 (-73%).
McKesson
MCK · USD · Health Care
-7%
upside to fair value
fairly valued
Price$881
Fair Value$819
Quality66/100
Novolog Pharm-Up 1966
NVLG.TA · ILA · Health Care
-73%
upside to fair value
overvalued
PriceILS 0.84
Fair ValueILS 0.23
Quality43/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

McKessonNovolog Pharm-Up 1966
Valuation
23.0×P/E (TTM)80.9×
0.27×P/S (TTM)0.08×
Negative equityP/B0.38×
16.1×EV/EBITDAn/a
1.57×PEGn/a
−6.9%Fair value upside−72.6%
0.4%Dividend yield4.8%
$3.17Dividend per shareILS 0.04
Profitability
2%Operating margin1%
1.60×EBIT margin trend (5Y)0.28×
Negative equityReturn on equity1%
5%Return on assets1%
Growth
6%Revenue growth (YoY)-0%
13.4%Avg. growth/yr (3Y)6.2%
11.1%Avg. growth/yr (5Y)9.8%
+40.2%Value creation/yr−32.4%
Balance & size
26.1×Interest coverage (EBIT/interest)1.4×
Negative equityDebt / equityn/a
$109BMarket cap$136M
healthyGrowth qualityexpensive

McKesson leads: 10 to 2 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

McKessonof which business quality 65 · market factors 65 Novolog Pharm-Up 1966of which business quality 41 · market factors 35
ProfitabilityMargins and returns on capital today
49
25
Quality GrowthAre margins and returns improving?
65
40
CashflowEarnings quality: real cash, not paper profit
47
11
Fin. StrengthBalance sheet, leverage, solvency risk
72
29
InvestmentDisciplined investing over empire-building
76
100
Low VolatilityCalm price path (market factor)
83
77
MomentumPrice trend over the last 3–12 months (market factor)
56
21
52W MomentumDistance to the 52-week high (market factor)
60
13
Net IssuanceShare count: buybacks or dilution?
100
83

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyMcKessonPrice $881Novolog Pharm-Up 1966Price ILS 0.84
DCF Models+10%close to the price$969+176%above the priceILS 2.32
Earnings-Based-50%below the price$444-82%below the priceILS 0.16
Dividend Discount-93%below the price$57.26-47%below the priceILS 0.45
Multiples-4%close to the price$848-35%below the priceILS 0.55
Asset-Basedn/a-44%below the priceILS 0.47
Growth DCF+7%close to the price$944n/a
Economic Profit-44%below the price$497-40%below the priceILS 0.51
Growth Earnings-20%below the price$708-83%below the priceILS 0.14
Minimum-93%below the price$57.26-83%below the priceILS 0.14
Maximum+10%close to the price$969+176%above the priceILS 2.32
Median-20%below the price$708-44%below the priceILS 0.47
Geometric mean-44%below the price$492-48%below the priceILS 0.43

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

McKesson: 13 of 23 models see the stock below the current price.

Novolog Pharm-Up 1966: 13 of 17 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

McKesson
Price $881
Fair Value $819
Bear $605Bull $1,034
Novolog Pharm-Up 1966
Price ILS 0.84
Fair Value ILS 0.23
Bear ILS 0.13Bull ILS 0.24

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

McKesson · Health Care

Quality score66 · Top 25%
Fair value upside-7% · above median

Novolog Pharm-Up 1966 · Health Care

Quality score43 · below median
Fair value upside-73% · bottom 25%

Bottom line

As of Sep 25, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: McKesson trades at $881 versus a fair value of $819 (-7%), while Novolog Pharm-Up 1966 trades at ILS 0.84 versus ILS 0.23 (-73%).

McKesson has the higher quality score (66/100).

Open McKesson live analysis →
McKesson · Novolog Pharm-Up 1966

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to McKesson

Microsoft vs NvidiaApple vs MicrosoftNvidia vs Taiwan Semiconductor ManufacturingApple vs Taiwan Semiconductor Manufacturing

Related to Novolog Pharm-Up 1966

Alphabet Inc Class C vs Meta PlatformsCisco Systems vs NvidiaMicrosoft vs Taiwan Semiconductor ManufacturingApple vs Cisco Systems
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.